Publication: Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study
cris.virtual.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
cris.virtual.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
cris.virtual.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
cris.virtual.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
cris.virtual.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
cris.virtual.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
cris.virtual.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
cris.virtual.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
cris.virtual.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
cris.virtualsource.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
cris.virtualsource.author-orcid | bed2f732-ad8f-46da-b23e-e9db6529c5f6 | |
cris.virtualsource.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
cris.virtualsource.author-orcid | d15fbd74-75d8-4d5c-af34-c5ddef96dc39 | |
cris.virtualsource.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
cris.virtualsource.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
cris.virtualsource.author-orcid | 3ada9c2f-a4dd-4760-84b1-c48e64972bc5 | |
cris.virtualsource.author-orcid | f34c7371-748b-4478-8d2e-40dddd291954 | |
cris.virtualsource.author-orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
dc.contributor.author | Mueller, F | |
dc.contributor.author | Büchel, Barbara | |
dc.contributor.author | Köberle, D | |
dc.contributor.author | Schürch, Stefan | |
dc.contributor.author | Pfister, B | |
dc.contributor.author | Krähenbühl, St | |
dc.contributor.author | Fröhlich, Tanja | |
dc.contributor.author | Largiadèr, Carlo Rodolfo | |
dc.contributor.author | Joerger, M | |
dc.date.accessioned | 2024-10-11T13:37:27Z | |
dc.date.available | 2024-10-11T13:37:27Z | |
dc.date.issued | 2013 | |
dc.description.abstract | This study was initiated to assess the quantitative impact of patient anthropometrics and dihydropyrimidine dehydrogenase (DPYD) mutations on the pharmacokinetics (PK) of 5-fluorouracil (5FU) and to explore limited sampling strategies of 5FU. | |
dc.description.numberOfPages | 10 | |
dc.description.sponsorship | Universitätsinstitut für Klinische Chemie (UKC) | |
dc.description.sponsorship | Departement für Chemie und Biochemie (DCB) | |
dc.identifier.doi | 10.48350/14661 | |
dc.identifier.isi | 000314044200010 | |
dc.identifier.pmid | 23139054 | |
dc.identifier.publisherDOI | 10.1007/s00280-012-2018-4 | |
dc.identifier.uri | https://boris-portal.unibe.ch/handle/20.500.12422/84720 | |
dc.language.iso | en | |
dc.publisher | Springer | |
dc.publisher.place | Berlin | |
dc.relation.ispartof | Cancer chemotherapy and pharmacology | |
dc.relation.issn | 0344-5704 | |
dc.relation.organization | DCD5A442BA49E17DE0405C82790C4DE2 | |
dc.relation.organization | DCD5A442C14DE17DE0405C82790C4DE2 | |
dc.subject.ddc | 600 - Technology::610 - Medicine & health | |
dc.subject.ddc | 500 - Science::570 - Life sciences; biology | |
dc.subject.ddc | 500 - Science::540 - Chemistry | |
dc.title | Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study | |
dc.type | article | |
dspace.entity.type | Publication | |
dspace.file.type | text | |
oaire.citation.endPage | 70 | |
oaire.citation.issue | 2 | |
oaire.citation.startPage | 361 | |
oaire.citation.volume | 71 | |
oairecerif.author.affiliation | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation | Universitätsinstitut für Klinische Chemie (UKC) | |
oairecerif.author.affiliation | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation | Departement für Chemie und Biochemie (DCB) | |
oairecerif.author.affiliation | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation | Universitätsinstitut für Klinische Chemie (UKC) | |
oairecerif.author.affiliation | Universitätsinstitut für Klinische Chemie (UKC) | |
oairecerif.author.affiliation | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation2 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation2 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation2 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation2 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation2 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation2 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation2 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation2 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation2 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation3 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation3 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation3 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation3 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation3 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation3 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation3 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation3 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation3 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation4 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation4 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation4 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation4 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation4 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation4 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation4 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation4 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
oairecerif.author.affiliation4 | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.date.licenseChanged | 2022-07-07 12:57:59 | |
unibe.description.ispublished | pub | |
unibe.eprints.legacyId | 14661 | |
unibe.journal.abbrevTitle | CANCER CHEMOTH PHARM | |
unibe.refereed | TRUE | |
unibe.subtype.article | journal |
Files
Original bundle
1 - 1 of 1
- Name:
- Mueller2013_Article_Gender-specificEliminationOfCo.pdf
- Size:
- 380.8 KB
- Format:
- Adobe Portable Document Format
- File Type:
- text
- License:
- publisher
- Content:
- published